10 February 2022: Clinical Research
A Single-Center, Randomized, Double-Blind Study of 94 Patients Undergoing Surgery for Cerebral Glioma to Compare Postoperative Thromboprophylaxis with and without Rivaroxaban
Zi-Yan Wang 1ABC , You-Dong Wan 2CDEF , Xian-Zhi Liu 1EFG , Hao Wang 1AD , Guang-Yi Jiang 1ABF , Bo Yang 1ABCDEFG*DOI: 10.12659/MSM.934341
Med Sci Monit 2022; 28:e934341
Table 3 Comparison of safety outcomes between rivaroxaban and placebo groups.
| Parameter | Rivaroxaban (n=47) | Placebo (n=47) | P value |
|---|---|---|---|
| Major bleeding events | 1 (2.1%) | 1 (2.1%) | |
| Fatal bleeding | 0 | 0 | |
| Critical bleeding | 0 | 0 | |
| Clinically overt bleeding | 1 (2.1%) | 1 (2.1%) | |
| Mild bleeding | 2 (4.2%) | 0 | |
| Thrombocytopenia | 0 | 0 | |
| VTE-related death | 0 | 1 (2.1%) | |
| Allergy | 0 | 0 |